The pharmaceutical industry is coming to the end of the blockbuster era, analysts say. allopurinol. Patent expiries and a steep drop-off in clinically significant innovation is forcing drug makers to develop new strategies for shoring up margins as pricing comes under increasing pressure from generic competition, health care programs, and mounting public outcry for change. Cost cutting is inevitable in every aspect of the business, analysts say, including R&D and marketing, where astronomical spending no longer boosts the bottom line.
Related Results
Primer for prescription medications — buspirone.(Buspar)
Pharmaceutical settlement will provide BuSpar reimbursements
Generics get a boost as court rules for Mylan
Fourth-Quarter Earnings Surge for Corona, Calif.-Based Drug Company.
Teva, Mylan Win Approval For Marketing Of Lovastatin.(Brief Article)
“The four-dollar pill costs 20 cts to make,” …
Read the rest of this article with a Free Trial at HighBeam Research.